Dr. Reshma Mahtani highlighted the SOFT and TEXT trials, showing a 3.8% absolute five-year DFS benefit for AI over tamoxifen in premenopausal patients. The NEOCARB study suggested carboplatin may be dispensable in early-stage HER2-positive disease.